✦ LIBER ✦

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

✍ Scribed by Nestle, Frank O.; Alijagic, Selma; Gilliet, Michel; Sun, Yuansheng; Grabbe, Stephan; Dummer, Reinhard; Burg, Günter; Schadendorf, Dirk

Book ID: 109927742
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 926 KB
Volume: 4
Category: Article
ISSN: 1078-8956
DOI: 10.1038/nm0398-328

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vaccination of Japanese patients with ad

Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells

✍ Noriaki NAKAI; Jun ASAI; Eiichiro UEDA; Hideya TAKENAKA; Norito KATOH; Saburo KI 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 280 KB

Long-term outcomes in patients with meta

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+progenitor-derived dendritic cells

✍ Joseph W. Fay; A. Karolina Palucka; Sophie Paczesny; Madhav Dhodapkar; Dennis A. 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 359 KB

Analysis of T-cell responses in metastat

Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates

✍ Marieke Griffioen; Martina Borghi; Peter I. Schrier; Susanne Osanto; Dirk Schade 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 213 KB

Vaccination of patients with B–cell lymp

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

✍ Hsu, Frank J.; Benike, Claudia; Fagnoni, Francesco; Liles, Tina Marie; Czerwinsk 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 806 KB

Phase I study in melanoma patients of a

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

✍ Andreas Mackensen; Birgit Herbst; Ji-Li Chen; Gabriele Köhler; Christoph Noppen; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 268 KB 👁 2 views

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that can be used for vaccination purposes, to induce a specific T-cell response in vivo against melanomaassociated antigens. We have shown that the sequential use of early-acting hematopoietic growth factors, stem cell factor, IL

Vaccination with p53-peptide–pulsed dend

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

✍ IngeMarie Svane; AndersE. Pedersen; HansE. Johnsen; Dorte Nielsen; Claus Kamby; 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 443 KB